지놈앤컴퍼니

314130KOSDAQ

55.3 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genom and Company aims to grow into a fully integrated pharmaceutical company by focusing on innovative drug development, utilizing its GNOCLE™ platform to advance pipeline candidates such as the immunotherapy GENA-104 and microbiome-based treatment GEN-001. The company also diversifies its business through CDMO services and its microbiome cosmetics brand 'UIQ'.

Number of Employees

96people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.57Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-7.20Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.62Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -23.6% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
지놈앤컴퍼니 GENA-120, 中 씨스톤 넘어 기술이전 기대감↑
지놈앤컴퍼니의 차세대 ADC 후보물질 GENA-120의 기술수출 성공으로 인해 긍정적인 시장 반응이 예상됩니다.
Positive
K-바이오, 'R&D 전쟁' 실탄 상반기에만 1조3000억 장전
국내 바이오 기업들의 대규모 자금 조달로 신약 개발 경쟁이 강화되어 지놈앤컴퍼니의 미래 성장 가능성이 높아짐.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 3,445Won52-week high 9,97052-week low 2,600

1-month return2.0Point

1m -5.10% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-08-21
Neutral주식매수선택권부여에관한신고2026-08-21
Neutral임시주주총회결과2026-08-21
Neutral파생상품거래손실발생2026-08-18
Neutral반기보고서 (2026.06)2026-08-14